Zhang Linfeng, Wang Mingfei, Ren Wenhao, Li Shaoming, Zhi Keqian, Gao Ling, Zheng Jingjing
Department of Stomatology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
School of Stomatology, Qingdao University, Qingdao, Shandong, China.
Oral Dis. 2023 May;29(4):1439-1453. doi: 10.1111/odi.14188. Epub 2022 Mar 27.
This systematic review was aimed to comprehensively evaluate the clinicopathological and prognostic value of dysregulated expression of circRNAs in OSCC. The research was carried out by searching mainstream electronic databases including PubMed, Embase, Web of Science, Scopus, LILACS, and Cochrane Library to collect relevant studies on prognostic role of circRNAs in OSCC. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the association between circRNAs expression, overall survival (OS), disease/recurrence/progression survival (DFS/RFS/PFS), and clinical parameters. This research included 1813 patients from 26 selected articles. The pooled HR values (95% CIs) in OS were 2.38 (1.92-2.93) for oncogenic circRNAs and 0.43 (0.28-0.66) for tumor-suppressor circRNAs, respectively, in DFS/RFS/PFS were 2.34 (1.73-3.17). The meta-analysis on clinicopathology features showed higher level of oncogenic circRNAs is related to advanced TNM stage, tumor stage, worse histological differentiation, positive lymph node and distant metastasis, while enforced expression of tumor-suppressor circRNAs is related to inferior TNM stage, tumor stage and lymphatic metastasis. In conclusion, our meta-analysis implies that circRNAs may be candidate biomarkers for the prognosis and clinicopathology of OSCC.
本系统评价旨在全面评估环状RNA（circRNA）表达失调在口腔鳞状细胞癌（OSCC）中的临床病理及预后价值。通过检索包括PubMed、Embase、Web of Science、Scopus、LILACS和Cochrane图书馆在内的主流电子数据库开展研究，以收集关于circRNA在OSCC预后作用的相关研究。计算合并风险比（HRs）和比值比（ORs）及95%置信区间（CIs），以评估circRNA表达、总生存期（OS）、疾病/复发/进展生存期（DFS/RFS/PFS）和临床参数之间的关联。本研究纳入了26篇选定文章中的1813例患者。在OS中，致癌circRNA的合并HR值（95% CIs）为2.38（1.92 - 2.93），肿瘤抑制circRNA的为0.43（0.28 - 0.66）；在DFS/RFS/PFS中为2.34（1.73 - 3.17）。对临床病理特征的荟萃分析表明，致癌circRNA水平较高与晚期TNM分期、肿瘤分期、较差的组织学分化、阳性淋巴结和远处转移相关，而肿瘤抑制circRNA的过表达与较低的TNM分期、肿瘤分期和淋巴转移相关。总之，我们的荟萃分析表明，circRNA可能是OSCC预后和临床病理的候选生物标志物。
